AZmed vs Gleamer (2026)
Two closely matched fracture detection aids from Paris, both FDA cleared for adults and children and both assistive, so the differences sit in the validation each publishes and the company behind it. AZmed's Rayvolve now covers fractures, dislocations and joint effusions across the limbs, pelvis, hip, spine and ribs under a 2026 clearance, with earlier clearances resting on studies at University Hospitals Cleveland and SimonMed and a 2026 multicenter analysis of 258,373 X-rays across 26 countries. Gleamer's BoneView FDA summary reports a 24 reader study, characterizes its training set and compares results between adults and children, and since March 2026 Gleamer has been part of DeepHealth, RadNet's digital health subsidiary. If your failure mode is breadth of trauma findings in one cleared product, start with AZmed. If it is published subgroup results and the backing of a large US imaging operator, start with Gleamer.
- Trauma scope is broad in one product, with Rayvolve cleared for fractures across the limbs, pelvis, hip, spine and ribs, dislocations at the shoulder, elbow and fingers, and effusions at the elbow, forearm and arm, in adults and children aged two and over.
- Validation spans many sites, with clearances resting on studies at University Hospitals Cleveland, where aided sensitivity rose from 0.865 to 0.955 with specificity nearly unchanged, and SimonMed, plus a 2026 analysis of 258,373 X-rays from 100 centers in 26 countries.
- Reach is wide, with use reported at more than 2,500 sites in more than 55 countries and 15.4 million X-rays analyzed in the last twelve months, and a CT suite, Rayscan, for lung nodules.
- Its FDA summary shows the work, with a 24 reader, 480 case study in which aided sensitivity rose from 0.648 to 0.752 and specificity from 0.906 to 0.956, and a training set of 44,649 radiographs described by sex and age.
- Results are compared between adults and children and across anatomical regions, so the regions where the model is weaker are visible.
- Output carries two confidence levels, a solid box for a high confidence fracture and a dotted box for a subtle one, at published operating points, and the company reports more than 60 million exams a year across more than 3,500 sites.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AZmed and Gleamer are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AZmed | Gleamer |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2018 | 2017 |
| Headquarters | Paris, France | Saint-Mandé, France |
| Website | azmed.co | gleamer.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Paris based imaging AI company whose Rayvolve suite reads plain radiographs: AZtrauma detects fractures, dislocations and joint effusions, AZchest covers chest findings including pneumothorax, pleural effusion and lung nodules, and AZmeasure and AZboneage add measurements and bone age. A second suite, Rayscan, detects lung nodules on CT.
Source: AI Health Index, July 2026
Gleamer SAS is a radiology AI company based in Saint-Mandé, on the edge of Paris, and since 2 March 2026 part of DeepHealth, the digital health subsidiary of the US imaging services operator RadNet, Inc. RadNet announced the all cash acquisition at up to 230 million euros, about 215 million at closing plus a 15 million contingent milestone. Gleamer's site and products keep the Gleamer name.
Source: AI Health Index, July 2026
Questions buyers ask
How do AZmed and Gleamer work with the EHR?
For AZmed, the company reports use at more than 2,500 sites in more than 55 countries and 15.4 million X-rays analyzed in the last twelve months, and its clearances rested on studies at named US institutions, University Hospitals in Cleveland and SimonMed Imaging. It has also been distributed through third party cloud radiology workflow platforms, including RADIN.
Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, since March 2026, and nothing published says whether the products now run inside DeepHealth's platform or remain available on other vendors' archives. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How are AZmed and Gleamer priced and sold?
In AZmed's case, the software has been sold both directly and through cloud radiology platforms. The company's scale figures, more than 2,500 sites in more than 55 countries, describe use, not price.
For Gleamer, the packaging and the owner are public. The products are sold as modules of the Gleamer Copilot suite, and since March 2026 Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, so contracting may run through DeepHealth. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How do AZmed and Gleamer handle patient data?
With AZmed, the home page describes SOC 2, GDPR and HIPAA compliant infrastructure. The privacy policy, approved in December 2025, covers the website, billing, prospecting and recruitment, with retention periods for those records only; it does not address images or outputs processed by Rayvolve or Rayscan.
When Gleamer receives patient data from a customer, including imaging examinations and reports, it acts as the customer's processor and works on pseudonymized data, and where the customer authorizes it, Gleamer may anonymize pseudonymized patient data and use the anonymized result for its own purposes, including training and developing its products. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
What evidence is published for AZmed and Gleamer?
For AZmed, a 2026 multicenter analysis by Cohen and colleagues covers 258,373 X-rays from 100 centers in 26 countries.
With Gleamer, the company reports more than 140 clinical studies and more than 60 publications, and its clinical studies library lists a systematic review of BoneView and emergency department studies. Independent evaluations of commercial fracture detection algorithms on real world emergency department data have also been published, though it is not clear whether they cover the BoneView version sold. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither vendor publishes a price or a security attestation of its own; AZmed calls its infrastructure SOC 2 compliant without saying whose report it is, and Gleamer names only ISO 13485, which covers its device quality system. Neither publishes business associate terms for US customers. Gleamer's privacy policy states that no data is transferred outside the European Union, while AZmed names no hosting region, and Gleamer's ownership by DeepHealth, a US company, may change both answers.
AZmed's headline figures, including a 99.7 percent negative predictive value, carry no method. An earlier version of this comparison said neither vendor publishes a data residency commitment; Gleamer's privacy policy states one. That statement was corrected on 10 October 2026.